Typical NeoScreen® Service Workflow
Immunitrack’s NeoScreen® platform can help your company to identify MHC-restricted CD4 or CD8 epitopes from any cancer, biotherapeutic, viral or bacterial pathogen, fast and with unmatched precision.
Next generation sequencing of tumour biopsies allows personalised identification of neo-epitopes (cancer-specific mutations). This information may reveal cancer-specific epitopes and can be used in many applications, including:
- Selection of neo-epitopes for the development of personalised cancer vaccines.
- Study of patient neo-epitope specific T cell responses before and after immunotherapy.
- Screening for new potential cancer-specific targets for immunotherapy development, such as CAR-T therapies and T cell receptor like antibodies.
Immunitrack’s NeoScreen® platform technology supports early stage immunotherapy development including personalised cancer vaccines and T-cell therapies.
NeoScreen® facilitates rapid high-throughput screening of major histocompatibility complex class I and II (MHC I & II) interactions with neo-epitopes to identify candidate epitopes for further development.
Find more information about NeoScreen® here ▸